Hospital-acquired infections coming down, says CDC

Hospital-acquired or hospital-linked infections, which are often said to lead to the deaths of as many as 100,000 people in the United States each year, are on the decline according to the Centers for Disease Control and Prevention in Atlanta (CDC).

The CDC has issued a report on the number of such infections for 2010, and the figures are down from where they were just a few years earlier. Specifically, the agency is reporting that these infections are down as much as 32%.

Infections that are reported include infections from the central line, as well as surgical site infections and catheter-associated urinary tract infections.

States in the US have begun mandating the reporting of all three types of infections, ever since the formation of the National Healthcare Safety Network in 2005. Currently 20 different states in the Union have such mandates in place.

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap